PUBLICATION IN ANNALS OF INTERNAL MEDICINE! ‘Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States’ [ Ann Intern Med ]
PUBLICATION IN PAPILLOMAVIRUS RESEARCH: ‘HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control’ [ Papillomavirus Research ]
LAVAL UNIVERSITY COMMUNITY REPORT. Marc Brisson’s research highlighted in Laval University’s 2018-19 community report. [ Report ]
SAGE-WHO 2019. Marc Brisson and Mélanie Drolet were present. Marc Brisson presented ‘Impact of HPV Immunization Strategies in the Context of Supply Constraint’ at the Strategic Advisory Group of Experts (SAGE) Working Group on Human Papillomavirus (HPV) Immunization, held in Geneva, Switzerland, October 8-10, 2019. [ Meeting Agenda (PDF) ]
WORKSHOP AT FIELDS INSTITUTE. JF Laprise took part to the workshop ‘Borders in Public Health and Mathematical Epidemiology’ held October 21-25, 2019, The Fields Institute, Toronto, Canada. [ Workshop schedule ]
SMDM 2019. Dave Martin will present ‘Health and Economic Impact of HPV Testing Compared to Cytology’ at the SMDM’s 41st annual meeting held in Portland, Oregon, USA, October 20-23, 2019. [ SMDM 2019 ]
ID WEEK 2019. Marc Brisson and Mélanie Drolet were present. Marc Brisson presented ‘Understanding the Science Behind Planning for Global Elimination of Cervical Cancer’, ID Week 2019 Conference, Washington, DC, USA, October 2-6, 2019. [ Program (PDF) ]
PUBLICATION IN CMAJ: ‘Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study’ [ CMAJ ]
PUBLICATION IN BMC MEDICINE: ‘Guidelines for multi-model comparisons of the impact of infectious disease interventions’ [ Pubmed ]
PUBLICATION IN VACCINE: ‘An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool’ [ Pubmed ]
PUBLICATION IN HUMAN VACCINES & IMMUNOTHERAPEUTIC: ‘Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study.’ [ Pubmed ]
PUBLICATION OF A WHITE PAPER for the Single Dose HPV Vaccine Evaluation Consortium: ‘Review of the current published evidence for single-dose HPV vaccination 2nd Edition’ [ pdf ]
WIDESPREAD MEDIA COVERAGE of our article published in The Lancet from local to national to international level (USA, UK, Australia, Spain, France, Norway, Denmark, Sweden, Hungary, Ireland, Argentina, Dominican Republic, Mexico, Kenya, India, Malaysia) [ Media ] [ Media tracking ]
PUBLICATION IN THE LANCET! ‘Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis’ [ TheLancet ]
CIHR FUNDING. Marc Brisson is a co-investigator of 3 newly CIHR funded projects :
1) Elimination of cervical cancer through vaccination and screening in high HPV prevalence settings : a mathematical modeling and cost-effectiveness study (Principal Investigator : Mathieu Maheu-Giroux) [CIHR 1] ;
2) Illiap Paanganik Qaujisarniq: Tailoring Cervical Cancer Screening Services for Inuit Women of Nunavik (Principal Investigator: Paul Brassard) [CIHR 2] ;
3) Is Ontario prepared for the return of measles? (Principal Investigator : Shelly Bolotin) [CIHR 3]
Our team’s work was part of the evidence base that informed the ACIP vote on recommendations to extend HPV vaccination to adults over 26 years of age in the US. [ CDC ]
NEW TEAM MEMBERS! Welcome to Léa Drolet Roy and Gabrielle Hudon, research assistants during the summer of 2019.
NEW TEAM MEMBERS! Welcome to Aurélie Godbout and Patricia Lamirande, who will undertake their Master degree in Epidemiology next fall.
SAGE-WHO WORKING GROUP MEETING. Marc Brisson presented ‘Optimal HPV vaccination strategies to prevent cervical cancer in LMIC: A mathematical modeling analysis’ at the Strategic Advisory Group of Experts (SAGE) Working Group on Human Papillomavirus (HPV) Immunization, held in Menthon St-Bernard, France, June 7, 2019.
PUBLICATION IN THE LANCET ONCOLOGY: ‘Global elimination of cervical cancer as a public health problem’ [ ScienceDirect ]
ACIP MEETING. Marc Brisson was presenting at the meeting of the Advisory Committee on Immunization Practices (ACIP): ‘Cost-Effectiveness of extending HPV vaccination above age 26 years in the U.S.’ (Atlanta, February 27) [ Meeting Agenda ]
EUROGIN 2018. Marc Brisson was chair of the session ‘Two vs one dose vaccine schedules: assessing the evidence’ at EUROGIN 2018 and was invited speaker presenting ‘Population-level impact of 1-dose vaccination in Low and Middle Income Countries vs High Income Countries: Model-based analysis’. (Lisbon, December 2-5) [ EUROGIN 2018 – PROGRAM (PDF) ]
EUROGIN 2018. Philippe Lemieux-Mellouki was presenting at EUROGIN 2018: ‘Impact of changes in sexual behavior on past and future trends of HPV infections and related cancers.’ (Lisbon, December 2-5) [ EUROGIN 2018 – PROGRAM (PDF) ]
SAGE-WHO MEETING. Élodie Bénard and Dave Martin were present at the meeting of the WHO Strategic Advisory Group of Experts (SAGE) on immunization held October 23-25, 2018, in Geneva.
SAGE-WHO MEETING. Marc Brisson presented at the meeting of the WHO Strategic Advisory Group of Experts (SAGE) on immunization held October 23-25, 2018, in Geneva. Results presented at the meeting will be used for WHO recommendations on HPV vaccination at the Global level.
IPVC 2018. Mélanie Drolet was presenting at the 32nd International Papillomavirus Conference: ‘Reduced-dose HPV vaccination effectiveness in post-vaccination surveillance studies: using mathematical modeling to quantify the impact of biases.’ (Sydney, October 2-6)
IPVC 2018. Marc Brisson was invited speaker at the 32nd International Papillomavirus Conference IPVC: ‘Modeling cervical cancer elimination’. He also presented: ‘The impact of HPV in the US : insights from comparing mathematical model predictions and surveillance data.’ (Sydney, October 2-6)
PUBLICATIONS IN VALUE IN HEALTH: ‘Model Comparisons of the Effectiveness and Cost-effectiveness of Vaccination: A Systematic Review of the Literature’ [ ScienceDirect ]
PUBLICATION IN VACCINE: ‘Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs’ [ ScienceDirect ]
Marc Brisson is member of the newly appointed Expert Panel on the Potential Socio-economic Impacts of Antimicrobial Resistance in Canada of the Council of Canadian Academies. The goal of the panel is to assess the impact Antimicrobial Resistance has on Canadians and the health care system. [ scienceadvice.ca ]
PUBLICATION IN THE INTERNATIONAL JOURNAL OF CANCER: ‘Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14 year old girls against human papillomavirus’ [ PubMed ]
GRANT. Marc Brisson is one of the principal investigators on a US$ 5 million grant to 8 independent research institutions from Bill & Melinda Gates Foundation: “HPV 1-dose: Accelerating evidence and implementation”. Marc Brisson’s team is one of the Expert Groups forming the HPV One Dose Consortium.
EUROGIN 2017. Marc Brisson was chair of the session ‘What have we learnt from population-wide HPV vaccination programs and how can it guide future vaccination policy?’ and was invited speaker presenting ‘Herd immunity effect’. (Amsterdam, October 8-11) [ EUROGIN 2017 ] [ Program (PDF) ]
EUROGIN 2017. Mélanie Drolet was invited speaker at EUROGIN 2017: ‘Evidence from post-vaccination studies in high-income countries’. (Amsterdam, October 8-11) [ EUROGIN 2017 ] [ Program (PDF) ]
EUROGIN 2017. Jean-François Laprise was presenting at EUROGIN 2017: ‘Health and economic impact of HPV testing compared to cytology: what is the optimal primary cervical cancer screening strategy for Canada?’ (Amsterdam, October 8-11) [ EUROGIN 2017 ] [ Program (PDF) ]
PUBLICATION IN THE JOURNAL OF INFECTIOUS DISEASES: ‘The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and post-vaccination data interpretation.’ [ Oxford Academic ]
PUBLICATION IN EPIDEMICS: ‘Modelling multi-site transmission of the human papillomavirus and its impact on vaccination effectiveness’ [ ScienceDirect ]
NEW TEAM MEMBER! Welcome to Guillaume Béraud (Postdoctoral Fellow)
Marc Brisson was at the World Health Organization’s workshop ‘WHO Blueprint Plan of Action – Designing a vaccine efficacy trial during Public Health Emergencies: Towards the development of guidelines and interactive tools’. The workshop was held 1-2 May 2017 in Annecy, France.
Marc Brisson has ranked 1st in the 2017-2018 Research Scholars Junior 2 competition of the ‘Fonds de recherche du Québec – Santé’ (FRQS).
Marc Brisson is a principal investigator on a $ 10 million grant for the Canadian Immunization Research Network (CIRN) obtained from the Public Health Agency of Canada (PHAC) and the Canadian Institutes of Health Research (CIHR).
PUBLICATION IN THE AMERICAN JOURNAL OF EPIDEMIOLOGY: ‘Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.’ [ PubMed ]
WHO IVIR-AC MEETING. Marc Brisson participated to the meeting of the Immunization and Vaccines Related Implementation Research (IVIR) Advisory Committee (IVIR-AC) on ‘Ad-Hoc Expert Consultation on Clinical Trials of Non-Specific Effects of Vaccines’ at Veyrier-du-Lac, France, January 30-31, 2017
NEW TEAM MEMBER! Welcome to Karine Larouche (Master Student in Epidemiology)
Our team’s research work is cited in ACIP’s recommendations for ‘Use of a 2-Dose Schedule Human Papillomavirus Vaccination’ [ CDC ]
SAGE-WHO MEETING. SAGE issued recommendations regarding introduction of HPV vaccination in low to middle income countries based partly on modeling results presented by Marc Brisson to SAGE in October 2016. [ WHO ]
INTERVIEW IN ‘PLANÈTE F’ MAGAZINE. Marc Brisson is interviewed about vaccinating boys against HPV [ Planète F ]
PUBLICATION IN LANCET PUBLIC HEALTH: ‘Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis’ [ Lancet Pub Health ] [ Accompanying Comment ]
SAGE-WHO MEETING. Marc Brisson presented at the meeting of the WHO Strategic Advisory Group of Experts (SAGE) on immunization held October 18-20, 2016 in Geneva. Results presented at the meeting will be used for WHO recommendations on HPV vaccination at the Global level. [ Meeting Agenda ] [ Summary Report ]
ACIP MEETING. ACIP voted to recommend a 2-dose HPV vaccination schedule in the US for girls and boys, based partly on modeling results presented by Marc Brisson to ACIP last June. [ CDC ]
PUBLICATION IN EMERGING INFECTIOUS DISEASES: ‘Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes’ [ Free PMC Article ]
PUBLICATION IN CMAJ: ‘Effect of HPV on cervical cancer screening in Alberta.’ [ PubMed ]
PUBLICATION IN PLOS ONE: ‘Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review.’ [ Free PMC Article ]
PUBLICATION IN THE LANCET PUBLIC HEALTH: ‘Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models’ [ The Lancet ]
ACIP MEETING. Marc Brisson was presenting at the meeting of the Advisory Committee on Immunization Practices (Atlanta, June 22-23) [ Summary Report ] [ Meeting Agenda (PDF) ]
EUROGIN 2016. Marc Brisson was chair of the session ‘The role of modeling and economics’ and was invited speaker at EUROGIN 2016: ‘What can models tell us about reduced dose schedules?’ (Salzburg, June 15-18) [ EUROGIN 2016 ] [ Program (PDF) ]
WHO IVIR-AC MEETING. Marc Brisson attended the Immunization and Vaccines Related Implementation Research (IVIR) Advisory Committee (IVIR-AC) of the World Health Organization (WHO) (Geneva, May 30-June 1)
PUBLICATION IN THE JOURNAL OF INFECTIOUS DISEASES: ‘Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.’ [ J Infectd Dis ]
CONGRATULATIONS TO TALIA! Talía Malagón successfully defended her PhD thesis and obtained the grade of Philosophiae Doctor on May 24th, 2016.
CONGRATS LÉA! Léa Drolet-Roy was awarded a bronze medal and a $ 1,000 university scholarship for her project VSV-EBOV contre Ebola at the Canada-Wide Science Fair (CWSF) held last May at McGill University, Montreal. Léa is a high school student coached by our team. [ Collège Saint-Charles Garnier ]
Marc Brisson has been appointed full professor at Laval University.
CONGRATS LÉA! Léa Drolet-Roy, a high school student coached by our team, was awarded a prize at the ‘Super Expo-sciences Hydro-Québec, Finale Québécoise’ 2016 for her transmission-dynamic modeling project ‘VSV-EBOV contre Ébola’. Léa will be part of the Quebec delegation at the Canada-Wide Science Fair, Montreal May 15-20, 2016. [ CWSF ]
PUBLICATION IN VACCINE: ‘Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada’ [ PubMed ]
PUBLICATION IN THE INTERNATIONAL JOURNAL OF CANCER: ‘Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines’ [ Int J Cancer ]
PUBLICATION IN THE JOURNAL OF INFECTIOUS DISEASES: ‘The Impact and Cost-Effectiveness of 3 doses of 9-Valent Human Papillomavirus (HPV) Vaccine among US Females Previously Vaccinated with 4-Valent HPV Vaccine’ [ J Infect Dis ]
TEACHING AT IMPERIAL COLLEGE. Marc Brisson is giving a Lecture entitled ‘Economic Evaluation: from uncertainty quantification to public health decision making’ (London, February 11, 2016)
WHO MEETING. Marc Brisson is participating in the WHO Ad-hoc Consultation on Epidemiological Studies for Non-Specific Effects of Vaccines (Geneva, 16-17 February 2016)
RAC 2016 AWARDS. Our proposal ranked “Outstanding” in Compute Canada’s Resource Allocation Competition (RAC) 2016 and we received a 408 core-year allocation on Colosse supercomputer at Laval University, Quebec. [ Compute Canada ]
PUBLICATION IN EMERGING INFECTIOUS DISEASES: ‘Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior’ [ CDC ]
NEW TEAM MEMBER! Welcome to Dave Martin (Research professional)
Marc Brisson has joined the AIDS and Infectious Disease Network as a nominated researcher [ FRQS ]
PUBLICATION IN EPIDEMIOLOGY AND INFECTION: Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus [ Epidemiol Infect ]
PUBLICATION IN JNCI: ‘Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States’ [ JNCI ]
CIHR FUNDING! Marc Brisson awarded a Foundation Scheme grant as Nominated PI ($ 2,384,146 over 7 years): ‘Using mathematical modeling and health economics to evaluate and optimize infectious disease prevention strategies’ [ CIHR ]
PUBLICATION in Lancet Oncology: ‘Fewer than three doses of HPV vaccine’ [ The Lancet Oncology ]
WHO IVIR-AC MEETING. Marc Brisson attended the Immunization and Vaccines Related Implementation Research (IVIR) Advisory Committee (IVIR-AC) (Geneva, June 8-12)
CONGRATS ÉLODIE! Élodie Bénard was awarded the 1st prize for the best presentations at the ”Journée de la recherche des étudiants 2015 – Santé des populations et pratiques optimales en santé (SP-POS)”
NEW TEAM MEMBERS! Welcome to Guillaume Gingras (Post-doctoral fellow in infectious disease modelling, PhD in Physics) and to Myriam Rousseau (Master student in Epidemiology, BSc in Actuarial Science)
PUBLICATION IN THE LANCET ID: Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis [ The Lancet ID ] The publication was accompatnied by a comment [ Comment ]
INTERVIEWS IN SCIENTIFIC AMERICAN and ‘LE FIL’ MAGAZINE about our BMJ paper (Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model BMJ 2015;350:g7584) [ Scientific American ] [ Le Fil ]
Philippe Lemieux-Mellouki received a Michael Smith Foreign Study Supplement from CIHR ($ 6,000), to spend 4 months at London School of Hygiene and Tropical Medicine.
PUBLICATION IN BMJ: Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission mode [ BMJ ]